Introduction
The Abl oncogenes encode activated nonreceptor tyrosine kinases that cause cancer in mice and human. The Abl proteins include the retrovirally transduced product of Abl, v-Abl, and the product of chromosomal translocations found in human leukemias BCR-ABL and TEL-ABL. There is increasing evidence suggesting that the full transforming activity of Abl involves the activation of several signaling pathways including Ras, PI3K/AKT and JAK/STAT/Pim (Danial and Rothman, 2000; Kharas and Fruman, 2005; Chen et al., 2008; Tao et al., 2008) . For example, previous results suggested that v-Abl-induced AKT activation is a critical signaling pathway in v-Abl-induced cytokine-independent cell growth (Oki et al., 2002) . In addition, a report from other group showed that signal transmitted through AKT is important in modulating apoptosis in v-Abltransformed Pre-B cells (Gong et al., 2004) . It has also been revealed that the PI3K/AKT pathway contributes to transformation by BCR-ABL (Skorski et al., 1997; Kharas et al., 2008) . Importantly, it was found that PI3K inhibitors synergize with Abl kinase inhibitor imatinib by markedly increasing apoptosis of leukemia patient cells expressing BCR-ABL (Klejman et al., 2002) . However, the precise mechanisms of AKT activation in Abl-expressing cells are not fully understood.
AKT1, AKT2 and AKT3 isoforms identified in mice and human constitute a distinct family of serine/threonine kinases, which has been implicated in diverse cellular processes, including proliferation, cell survival, metabolism and tumor cell invasion (Vivanco and Sawyers, 2002; Li et al., 2007) . The PI3K/AKT pathway is frequently activated in a variety of human cancers and is considered an attractive target for the development of novel chemotherapeutic agents. The activation of PI3K/AKT signaling in cancers is mainly due to loss of function of the tumor suppressor phosphatase and tensin homolog (PTEN) and activating mutations of PIK3CA gene, which encodes the p110 a-catalytic subunit of PI3K (Samuels et al., 2005; Manning and Cantley, 2007) . The lipid kinase PIK3CA and the phosphatase PTEN exert their effect as regulators of AKT pathway by controlling the cellular levels of phosphatidylinositol-3,4,5-trisphosphate.
Although it is clear that the constitutively active Gag-AKT fusion protein produced by retrovirus is able to induce carcinogenesis (Ahmed et al., 1993) , activating somatic mutations in AKT1 gene have long been remained elusive. Interestingly, a recent report identified an oncogenic somatic mutation in the pleckstrin homology domain of AKT1 that results in a glutamic acid to lysine substitution at amino-acid 17 (E17K) (Carpten et al., 2007) . This mutation results in constitutive activation of AKT1, and leads to cellular transformation and the development of leukemia in mice. Furthermore, recent evidence indicates that the molecular mechanism underlying activation of AKT1(E17K) is a broadened target lipid selectivity that allows high-affinity binding to PI(4,5)P2 (Landgraf et al., 2008) . AKT1(E17K) mutation has been reported in various human cancers, including breast cancers, colorectal cancers, ovarian cancers, squamous cell carcinoma of the lung, endometrial carcinomas, urothelial carcinoma and bladder cancer, but not in other multiple human malignancies, including acute leukemias and liver cancers (Carpten et al., 2007; Kim et al., 2008; Mahmoud et al., 2008; Malanga et al., 2008; Mohamedali et al., 2008; Riener et al., 2008; Shoji et al., 2009; Zilberman et al., 2009; Askham et al., 2010) . These studies suggested that AKT1(E17K) mutation occurs at a low frequency and in a tissue-specific manner. Therapeutic efforts aimed at selective targeting this mutant could be effective in specific cancer types (Brugge et al., 2007; Bleeker et al., 2008) . However, the precise role of AKT1(E17K) in tumorigenesis remains to be further explained.
It is still unclear whether the AKT1(E17K) mutation is present in Abl-transformed cells. Because Abl-induced activation of the PI3K/AKT pathway is important in cellular transformation, we assayed for the presence of the AKT1(E17K) mutation in v-Abl-transformed cell clones. Moreover, we determined the possible role AKT1(E17K) mutation has in Abl transformation. Interestingly, recent studies have showed that the kinases AKT and Pim exhibit feedback relationship in several cell types (Hammerman et al., 2005; Muraski et al., 2007) . Like AKT, Pim-1, Pim-2 and Pim-3 are serine/threonine kinases that constitute a distinct family involved in cell proliferation and survival. Pim kinases show similar substrate specificity as AKT. Our previous studies have uncovered that Pim-1 and Pim-2 kinases are required for efficient Pre-B-cell transformation by v-Abl oncogene (Chen et al., 2008) . However, it is currently unclear whether an interaction exists between AKT and Pim signaling in Abl transformants. These prompted us to further address the relationship between AKT and Pim by determining if activated AKT can complement Pim kinase deficiency for survival of v-Abltransformed cells.
Results

AKT1(E17K) mutation was identified in a small proportion of v-Abl transformants
Several recent studies discovered an oncogenic AK-T1(E17K) mutation in multiple human malignancies. To determine the prevalence of AKT1(E17K) mutation in Abl-transformed cells, we analyzed 116 v-Abl-transformed cell clones for the AKT1(E17K) mutation by using single-strand conformation polymorphism assay (SSCP) and direct DNA sequencing. The PCR-SSCP analysis of the AKT1 exon 3 revealed aberrantly migrating bands in three v-Abl-transformed cell clones (3 of 116; 2.6%, clones nos. 47, 91 and 106), but not in other clones. We repeated the PCR-SSCP twice to confirm the specificity of the results. Then the DNA was extracted from the aberrantly migrating bands and was amplified by PCR. DNA sequence analysis revealed that the aberrant bands represented an identical point mutation in the pleckstrin homology domain of mice AKT1 (G4A mutation at nucleotide 49 that results in a lysine substitution for glutamic acid at amino-acid 17 (AKT1(E17K)) (Supplementary Figure S1) . We also performed mutation analysis by direct sequencing of PCR products and found that the data were consistent. None of the normal samples from 12 mice used for vAbl-mediated transformation showed evidence of AKT1 mutation by PCR and DNA sequencing analysis, indicating that the mutations had risen somatically. AKT1(E17K) significantly promotes v-Abl-mediated cellular transformation but is not sufficient to transform primary bone marrow cells To directly show the involvement of AKT1(E17K) mutation in v-Abl-mediated tumorigenesis, we generated bicistronic retroviruses encoding the p120 form of v-Abl and green fluorescent protein (GFP), AKT1 wildtype (AKT1(WT)), Myr-AKT1 or the AKT1(E17K) (Figure 1a ). Equal titer viruses were used to infect primary bone marrow cells freshly isolated from 129 strain mice. Infected cells were seeded on cytokine-free media in 96-well plates, and the ability of these viruses to transform bone marrow cells was assessed by counting the number of v-Abl-transformed cell clones generated in 96-well plates as previously described (Chen et al., 2008) . As shown in Figure 1b (Figure 1b) . To determine whether the E17K mutation alone is sufficient to transform primary bone marrow cells, we used pMIG (MSCV-IRES-GFP) vector to generate retroviral constructs that encode GFP and either AKT1(WT) or AKT1(E17K) (Figure 1a) . None of the plates seeded with cells infected with these viruses showed growth in any wells (data not shown). Together, these results show that AKT1(E17K) mutation significantly promotes v-Abl-mediated cellular transformation and suggest that AKT1(E17K) alone is not sufficient to transform primary murine bone marrow cells.
E17K mutation increases AKT1 activation in v-Abl transformants
Previous studies have shown that exogenous AK-T1(E17K) expressed in NIH3T3 cells has higher activity as compared with AKT1(WT) (Carpten et al., 2007) . To confirm the importance of AKT1 activity in v-Abl transformation, we examined the levels of AKT phosphorylation in the above v-Abl-transformed cell clones. Two independent cell clones expressing Flagtagged AKT1(WT), Myr-AKT1, AKT1(E17K) or GFP were used in this study. Western blotting analysis was performed using whole-cell extracts from these cell clones either not treated or treated with imatinib, an Abl kinase inhibitor. We found that both AKT1(E17K) and Myr-AKT1 presented higher levels of AKT phosphorylation compared with AKT1(WT) although the expression levels of AKT1(WT), AKT1(E17K) and Myr-AKT1 were similar in these cells (Figure 2a ; Supplementary Figure S2 ). When the v-Abl kinase was inactivated by imatinib, the phosphorylation level of AKT1(WT) dramatically decreased (Figure 2a, right) . In contrast, both AKT1(E17K) and Myr-AKT1 showed significant levels of phosphorylation after treatment with imatinib ( Figure 2a, right) . Furthermore, we found that when AKT proteins were isolated by immunoprecipitation, kinase activity was 3.8-fold higher in the AKT1(E17K) than in the AKT1(WT) in the absence of imatinib ( Figure 2b ). Interestingly, AKT1(E17K) kinase activity was approximately 13.0-fold higher than that of AKT1 mutation promotes v-Abl transformation G Guo et al AKT1(WT) in the presence of imatinib (Figure 2b ). These results suggest that the relative degree of inhibition by imatinib was greater for the AKT1(WT) than it was for the AKT1(E17K). To test whether AKT1(E17K) is phosphorylated in a PI3K-dependent manner, we used LY294002, a PI3 kinase inhibitor in this study. LY294002 greatly inhibited AKT1 phosphorylation in mutant clones, indicating that phosphorylation of AKT1(E17K) is largely PI3K dependent (Supplementary Figure S3) .
Cellular localization of AKT1(E17K) in the v-Abl transformants
Previous results also showed that the E17K mutation of AKT1 alters the protein's subcellular localization, increasing the presence of AKT1 to the plasma membrane when examined by transient expression in NIH 3T3 cells (Carpten et al., 2007) . To determine whether the E17K mutation alters AKT1 localization in the v-Abl-transformed cells, we performed immunofluorescence staining to investigate cellular distribution of the protein. As shown in Figure 3a , although significant amount of AKT1(WT) was detected in the rim of plasma membranes, AKT1(WT) was found throughout the cell after treatment with imatinib. In contrast, AKT1(E17K) was mainly detected in the plasma membrane in the absence of imatinib and significant amount of AKT1(E17K) was still localized to the membrane after the treatment with imatinib ( Figure 3a; Supplementary Figure S4) . To confirm such enhanced membrane localization of AKT1(E17K) in v-Abl transformants, we analyzed protein extracts enriched in cytosol and membranes by western blot. Our experiments revealed that both AKT1(WT) (Figure 3b , lanes 1 and 3) and AKT1(E17K) (Figure 3b , lanes 2 and 4) were found in the membrane and cytosol fractions without imatinib treatment (Figure 3b, left) . However, the levels of total AKT1 and phosphor-AKT1 in the membrane fraction were clearly higher in the AKT1(E17K)-expressing cells than that in the AKT1(WT)-expressing cells following treatment with imatinib (Figure 3b, right) . Together, these results suggest that the membrane localization of E17K mutant in v-Abl transformants is in part independent from Abl kinase activity.
AKT1(E17K)-expressing v-Abl transformants are highly resistant to apoptosis induced by imatinib
It has been well recognized that AKT signaling is a critical regulator of apoptosis (Amaravadi and Thompson, 2005) . Because E17K substitution affects the subcellular location of AKT1 and enhances its activity, we explored whether this mutation conferred resistance to apoptosis in v-Abl transformants in response to imatinib treatment. To address this question, we treated the v-Abl-transformed cells expressing AKT1(WT), AKT1(E17K) or GFP with imatinib and the percentage of viable cells were compared in these groups. As measured by the propidium iodide/Annexin V binding assay, v-Abl-transformed pre-B cells initiated apoptosis following 1.5 mM imatinib treatment, and under this culture condition, 35% of control cells expressing GFP remained viable after an exposure to imatinib for 24 h (Figure 4a) . Viability of the cells expressing AKT1(WT) was 37% after treatment with the inhibitor for 24 h, a result comparable to that of the GFP-expressing cells. In contrast, cells expressing AKT1(E17K) died at a slower rate. Cells expressing this mutant were viable under the same culture conditions (Figure 4a ). To determine whether ectopic overexpression of the mutant protein reflected the physiological conditions in cells containing an endogenous mutation, we examined the apoptosis in the cells carrying a naturally occurring somatic AKT1(E17K) mutation (Supplementary Figure S1) . We observed that endogenous AKT1(E17K) conferred resistance to apoptosis after exposure to imatinib (Figure 4b ). Endogenous AKT1(E17K) had higher activity as compared with AKT1(WT), a result similar to that obtained in cells ectopically expressing AKT1 (Supplementary Figure S5) . Together, these experiments show that E17K mutant increases the resistance of v-Abl transformants to apoptosis induced by imatinib. 1 and 3) or AKT1(E17K) (lanes labeled as 2 and 4) was carried out after treatment with or without imatinib, and isolated cytoplasmic or membrane proteins were probed as indicated. These results are representative of three identical experiments.
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Previous studies have suggested that altered apoptotic signaling in Abl-expressing cells is associated with increased expression of several antiapoptotic proteins, such as BCL2 and BCL-XL, and inactivation of proapoptotic protein BAD (Banerjee and Rothman, 1998; Horita et al., 2000; Chen et al., 2008) . Therefore, we analyzed the protein levels or phosphorylation status of these apoptotic proteins in v-Abl transformants expressing AKT1(WT), AKT1(E17K) or GFP. As shown in Figure 4c , expression of AKT1(E17K) caused upregulation of the levels of BCL2 as compared with AKT1(WT) and GFP. No significant change in the protein levels of BCL-XL was observed in cells expressing AKT1(WT), AKT1(E17K) or GFP (Figure 4d) . Interestingly, we found that the amount of phosphor-Ser136 BAD was increased in cells expressing AKT1(WT) as compared with control GFP, and expression of AKT1(E17K) further increased the level of the phosphorylation of BAD, although the total amount of BAD protein was not significantly affected by ectopic expression of these proteins (Figure 4e ).
AKT1(E17K) delays apoptosis induced by imatinib by regulating BCL2 and BAD after the loss of v-Abl kinase activity
Previous experiments have shown that BCL2 protein levels decline after the loss of v-Abl kinase activity (Horita et al., 2000; Chen et al., 2008) . In an attempt to gain a better understanding of the molecular basis of the altered apoptosis profile in AKT1(E17K)-expressing cells, we evaluated the protein levels or phosphorylation status of BCL2 and BAD in the v-Abl-transformed cells ectopically expressing AKT1(WT), AKT1(E17K) or GFP. Activation of AKT1 was examined in these cells treated in a time course with imatinib. As expected, AKT1(E17K) showed higher phosphorylation levels of AKT when compared with AKT1(WT) after treatment with imatinib (Figure 5a ). Interestingly, we observed that expression of AKT1(E17K) delayed loss of BCL2 protein levels on v-Abl inactivation ( Figure 5b ). As shown in Figure 5c , treatment with imatinib resulted in inhibition of phosphorylation of BAD. However, AKT1(E17K) delayed loss of phosphor-Ser136 BAD compared with AKT1(WT) and GFP control (Figure 5c ). These experiments suggest that AK-T1(E17K) may delay imatinib-mediated cell death by regulating BCL2 and BAD when v-Abl kinase activity is inhibited.
AKT1(E17K) promotes survival of Pim-deficient cells
Recent studies have revealed that AKT and Pim-1 show feedback relationship in some cell types (Muraski et al., 2007) . It has also been found that AKT shows similar substrate specificity as Pim kinases. These observations prompted us to examine the AKT expression and /Pim-3 À/À and wild-type mice (Chen et al., 2008) . Western blotting assay was performed and quantified. In comparison with wild-type cells, the levels of AKT protein were increased by approximately 40% and AKT phosphorylation by 34% in three independent Pim-deficient cell lines (Figure 6a ). These results suggest that reciprocal signaling between AKT and Pim may exist.
Next, we investigated whether ectopic expression of AKT had any effect on survival of Pim-deficient v-Abl transformants. To this end, we generated v-Abl-transformed Pim-1
À/À cells (triple knockout, TKO) ectopically expressing AKT1(WT), AKT1(E17K) or GFP (empty vector) using bicistronic retroviruses (Supplementary Figure S6) . Results from western blot assay showed that the cells infected with the retroviruses encoding AKT1(WT) or AKT1(E17K) expressed comparable levels of these proteins ( Figure 6b ). As shown in Figure 6c , cell survival was then examined following 1.0 mM imatinib treatment. Under this culture condition, 53% of v-Abl-transformed wild-type cells remained viable after 24 h of imatinib treatment. In contrast, only 22% of TKO cells expressing GFP and 25% of TKO cells expressing AKT1(WT) remained viable under same condition. However, 41% of TKO cells expressing AKT1(E17K) were viable after an exposure to imatinib for 24 h, suggesting that AKT1(E17K) promotes survival of Pim-deficient cells. Consistent with these results, subsequent western blot analysis revealed that AKT1(E17K) also showed an increased phosphorylation level in Pim-deficient v-Abl transformants compared with AKT1(WT) (Figure 6b) . To understand the survival-promoting effect of AKT1 (E17K) in TKO cells, we examined the protein levels or phosphorylation status of BCL2 and BAD in TKO cells expressing AKT1(WT), AKT1(E17K) or GFP. Although only slight increase of phosphor-Ser136 BAD level was observed in TKO cells expressing AK-T1(E17K) (data not shown), expression of BCL2 was significantly upregulated in TKO cells expressing AKT1(E17K) compared with TKO cells expressing AKT1(WT) (Figure 6d ). This pattern of BCL2 expression correlated with cell viability.
Because induction of Pim-1 expression has recently been linked to AKT activation (Muraski et al., 2007) , we explored whether AKT1(E17K) can regulate levels of Pim proteins in v-Abl transformants. To this end, we used v-Abl-transformed wild-type cells ectopically expressing AKT1(WT), AKT1(E17K) or GFP. Again, the E17K mutation increased AKT1 activation by showing higher phosphorylation levels compared with AKT1(WT) (Figure 7a ). No significant differences in the protein levels of Pim-1 and Pim-2 were observed among cells expressing AKT1(WT), AKT1(E17K) or GFP when v-Abl kinase was activated. As expected, time course studies showed that the levels of Pim-1 and Pim-2 in cells expressing either AKT1(WT) or GFP dramatically decreased after treatment with imatinib for 5 h (Figures 7b-d) . However, v-Abl transformants expressing AKT1(E17K) had increased levels of Pim-1 after exposure to imatinib for 5 h regarding the control cells. 
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A significant amount of Pim-2 protein also remained after 5 h of treatment with imatinib. These assays may support a role for AKT1 activation in regulation of the protein levels of Pim-1 and Pim-2 on v-Abl inactivation.
Discussion
Malignant transformation of lymphoid and myeloid cells involves the dysregulation or mutation of genes including PI3K/AKT pathway and Pim families that are normally involved in regulating the proliferation and survival of hematopoietic cells (Pasqualucci et al., 2001; Amaravadi and Thompson, 2005; Deutsch et al., 2007; Horn et al., 2008) . These altered genes cooperate to endow the transformed cells with cytokine-independent growth. Understanding hematopoietic tumorigenesis requires examination of these genetic alterations and dissection of the mechanisms of how the products of these altered genes cause the expansion of the malignant clone. Although the Abl oncogene has been extensively studied, the exact mechanisms that underlie Ablmediated cellular transformation are not fully understood. It has been reported that Abl-induced activation of the PI3K/AKT pathway is important in Ablmediated tumorigenesis (Oki et al., 2002; Kharas and Fruman, 2005) . A recent study found a somatic mutation in AKT1 (AKT1(E17K)) that results in constitutive activation of AKT1 (Carpten et al., 2007) . Although AKT1(E17K) has recently been implicated in several oncogenic processes, whether it is present in v-Abl-transformed cells is unknown. To address this issue, we performed the mutation analysis, and found that AKT1(E17K) mutation was present in a small proportion of v-Abl transformants. Our study results represent the first report of AKT1(E17K) mutation in Abltransformed cells. To further confirm the functional relevance of AKT1(E17K) mutation in v-Abl-mediated transformation, we used the bicistronic retroviruses encoding the v-Abl and either AKT1(E17K) or controls. We observed that retroviruses expressing v-Abl and AKT1(E17K) showed much higher ability to transform pre-B cells as compared with controls. These experiments provide, what we believe to be the first direct evidence, that AKT1(E17K) mutation promotes the cellular transformation by v-Abl oncoprotein. Although chronic lymphocytic leukemia and acute myeloid leukemia are not associated with AKT1(E17K) mutation (Zenz et al., 2008) , whether this mutation is present in Abl-induced human leukemias and provides prognostic significance in these leukemias has still to be determined. Activation of PI3K/AKT pathway has emerged as one of the essential signaling mechanisms in Abl oncogene-induced leukemogenesis (Kharas and Fruman, 2005) . Further mutation analysis of PI3K/ AKT signaling pathway will therefore be valuable in understanding primary or acquired resistance to imatinib treatment in these leukemias.
Our experiments have also provided insight into the mechanism by which AKT1(E17K) may affect survival of Abl transformants. First, our study data revealed that E17K mutation increases AKT1 activation in v-Abl transformants. Because AKT signaling is an important regulator of apoptosis, we then tested whether AK-T1(E17K) alters apoptosis profile in v-Abl-transformed cells. Previous study suggested that resistance to apoptosis in v-Abl-transformed pre-B cells is associated with increased expression of antiapoptotic protein BCL2 (Banerjee and Rothman, 1998) . However, inhibition of the Abl kinase activity with imatinib downregulates the expression of this antiapoptotic protein and induces apoptosis in v-Abl transformants. Importantly, we observed that expression of AKT1(E17K) resulted in upregulation of BCL2 expression and phosphorylation of BAD, thereby suppressing apoptosis induced by imatinib. The results reveal an antiapoptotic pathway triggered by AKT1(E17K) that contributes to the resistance of Abl-expressing cells to undergo imatinibmediated apoptosis. These findings may be useful not only to understand the mechanisms by which AKT1(E17K) promotes tumor development, but also to lead to the idea that multidrug regiments that specifically inhibit several pathways required for cellular growth or survival may be more effective in eradicating the specific cancer types.
Pim-1, Pim-2 and Pim-3 constitute another distinct family of serine/threonine kinases involved in cellular proliferation and survival. Increased expression of Pim kinases and mutation in the Pim genes have been shown in several types of human tumors including hematopoietic malignancies (Dhanasekaran et al., 2001; Bachmann and Moroy, 2005) . These data indicate that dysregulation of Pim kinases may be important for cellular transformation. Interestingly, there is increasing evidence that AKT kinase interplays with Pim kinases (Hu et al., 2009) . For example, a recent study suggested that Pim and AKT work in concert to regulate survival and proliferation of nontransformed hematopoietic cells (Hammerman et al., 2005) . More recently, another group described a novel discovery that Pim-1 is a crucial facet of cardioprotection downstream of AKT and that a feedback mechanism exists involving the two proteins (Muraski et al., 2007) . Importantly, Pim kinases show similar substrate specificity as AKT. For example, a recent study revealed that overexpression of Pim-1 increased PRAS40 phosphorylation at Thr246, an AKT phosphorylation site (Zhang et al., 2009) . In this study, we observed that Pim deficiency reduced PRAS40 phosphorylation at Thr246 in v-Abl transformants (Supplementary Figure S7) . Together, these data indicate that Pim and AKT are critical components of overlapping pathways.
Although Abl transformation is associated with AKT activation and induced Pim expression (Oki et al., 2002; Chen et al., 2008) , whether an interaction exists between AKT and Pim signaling in Abl oncogene-transformed cells is not fully understood. The data presented in this study provide evidence of reciprocal signaling between AKT and Pim in v-Abl transformants. Furthermore, our experiments showed that constitutively activated oncogenic form of AKT1 has marked effect on survival of Pim-deficient cells. It has been established that Pim kinases are expressed downstream of BCR-ABL and v-Abl signaling (Nieborowska-Skorska et al., 2002; Chen et al., 2008) , and that expression of Pim-1 and Pim-2 is inhibited by treatment with imatinib. Interestingly, our studies show that constitutively activated form of AKT1 is involved in the regulation of Pim expression when Abl kinase is inactivated by imatinib. On the basis of these findings, connections between these two families of kinases will need to be further examined in Abl-transformed cells.
Materials and methods
v-Abl-mediated transformation and cell culture Bone marrow cell transformation was performed and v-Abltransformed cell clones were generated and cultured as described previously (Chen et al., 2008) . Briefly, bone marrow cells were infected with free viruses carrying v-Abl oncogene by spin infection at 32 1C for 2 h. Infected cells were seeded in 96-well plates (each plate was equally seeded with four millions infected cells) and cultured under normal tissue culture conditions in RPMI 1640 supplemented with fetal calf serum. 96-well plates were then examined under a microscope to determine the v-Abl-transformed cell clones that showed cytokine-independent growth, and transformation efficiency was scored by counting the number of wells containing the survivors 2 weeks after infection.
Mutational analysis
Genomic DNA was extracted from v-Abl-transformed cell clones and corresponding normal bone marrow cells using DNA Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacture's guidelines. The DNA was amplified with one primer pair covering the AKT1 exon 3. The PCR products were directly sequenced and analyzed by SSCP and visualized by silver staining. Bands showing mobility shifts were reamplified and sequenced.
